Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Tumor markers: should we or shouldn't we?

N J McCarthy¹, S M Swain

¹National Cancer Institute, Medicine Branch, Building 10 RM 12N226, 10 Center Drive, Bethesda, MD 20892, USA.

Cancer Journal (Sudbury, Mass.)

|June 23, 2001

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges.

ESMO open·2025

Same author

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC).

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer.

NPJ breast cancer·2023

Same author

Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer.

ESMO open·2022

Same author

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.

Breast cancer research and treatment·2019